TREMFYA (guselkumab) Subcutaneous (SC) Induction Data Support Potential to Be the First and Only in Its Class to Offer the Option of Both Intravenous and SC Induction Therapy in Ulcerative Colitis
February 22, 2025
February 22, 2025
NEW BRUNSWICK, New Jersey, Feb. 22 -- Johnson and Johnson issued the following news release:
* * *
TREMFYA (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis
Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patients
The only SC induction data for an IL-23 inhib . . .
* * *
TREMFYA (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis
Phase 3 ASTRO study achieves primary and all secondary endpoints at Week 12 in ulcerative colitis patients
The only SC induction data for an IL-23 inhib . . .